Drug Trial News

RSS

Two peanut allergy treatments for children found to be highly effective at inducing remission

Researchers have discovered two peanut allergy treatments for children that are both highly effective at inducing remission.

7 Feb 2022

Drug used to treat skin and lung cancers slows the progression of ovarian cancer sub-type

A drug currently used to treat skin and lung cancers has been found to slow the progression of a form of ovarian cancer and increase the number of patients who respond to treatment, a clinical trial has found.

4 Feb 2022

Ketamine is rapid, safe, and effective in treating hospitalized suicidal patients

Ketamine is a fast acting, efficient treatment for patients hospitalized for severe suicidal thoughts (ideation), finds a clinical trial published by The BMJ today.

3 Feb 2022

Nanoparticle vaccine effective against eight SARS-CoV-2 variants in non-human primates

Researchers demonstrate that SARS-CoV-2 RBD-based nanoparticle vaccine induces neutralizing antibodies against SARS-CoV-2 variants.

2 Feb 2022

Experimental immunotherapy could help treat some people with metastatic breast cancer

An experimental form of immunotherapy that uses an individual's own tumor-fighting immune cells could potentially be used to treat people with metastatic breast cancer, according to results from an ongoing clinical trial led by researchers at the National Cancer Institute's Center for Cancer Research, part of the National Institutes of Health.

1 Feb 2022

Individual dosing of preparatory drug makes stem cell transplants safer for children

Individual dosing of a drug used to prepare children for stem cell transplantation makes this treatment safer. That's according to new research by scientists from the Princess Máxima Center and the Wilhelmina Children's Hospital.

1 Feb 2022

Open-label placebo shows promise as therapy for disorders of gut-brain interaction in children

Pain-predominant disorders of gut-brain interaction (DGBIs) in children - such as functional abdominal pain (FAP) and irritable bowel syndrome (IBS) - can lead to disabling symptoms, poor quality of life and high use of health care resources.

31 Jan 2022

New trial tests the effectiveness of hyperimmune immunoglobulin for hospitalized COVID-19 patients

This scanning electron microscope image shows SARS-CoV-2 (round gold particles) emerging from the surface of a cell cultured in the lab. SARS-CoV-2, also known as 2019-nCoV, is the virus that causes COVID-19.NIAID

28 Jan 2022

Study provides a new treatment option for patients with relapsed B-cell lymphoma

A new therapy showed improvement over the standard treatment for relapsed B-cell lymphoma, according to a study published in the New England Journal of Medicine.

26 Jan 2022

Homologous and heterologous COVID-19 booster vaccines found to be safe and immunogenic

In adults who had previously received a full regimen of any of three COVID-19 vaccines granted Emergency Use Authorization (EUA) or approved by the U.S. Food and Drug Administration, an additional booster dose of any of these vaccines was safe and prompted an immune response, according to preliminary clinical trial results reported in The New England Journal of Medicine.

26 Jan 2022

More than 5,000 people enrolled in PANORAMIC study for COVID-19 antivirals

Over 5,000 vulnerable people have now enrolled into a world-class study for the chance to receive life-saving antivirals, the government has announced today (Wednesday 26 January 2022).

26 Jan 2022

Eligible adults urged to take part in world-first COVID-19 study of antivirals

Adults over the age of 50 or with an underlying health condition who test positive for COVID-19 are being urged to sign up for a world-first COVID-19 study which is providing life-saving antivirals to thousands of people.

24 Jan 2022

Nirmatrelvir, Molnupiravir, and Remdesivir hold-up against SARS-CoV-2 Omicron variant in vitro

In a recent study posted to the bioRxiv* preprint server, researchers test three severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antivirals authorized for emergency use by the United States Food and Drug Administration (FDA) for their in vitro potency against several SARS-CoV-2 variants, including the currently dominant Omicron train.

23 Jan 2022

Trastuzumab combined with trimodality treatment for HER2-overexpressing esophageal cancer found to be ineffective

The NRG Oncology clinical trial NRG-RTOG 1010, studying the addition of the drug trastuzumab to chemoradiation and surgery, did not reach its primary goal of improving disease-free survival (DFS) rates for patients with HER2 overexpressing esophageal adenocarcinoma.

22 Jan 2022

New opportunity to induce remission of peanut allergy in young children through oral immunotherapy

A clinical trial funded by the National Institutes of Health has found that giving peanut oral immunotherapy to highly peanut-allergic children ages 1 to 3 years safely desensitized most of them to peanut and induced remission of peanut allergy in one-fifth. The immunotherapy consisted of a daily oral dose of peanut flour for 2.5 years.

21 Jan 2022

PAXLOVID shown to be highly effective against all SARS-CoV-2 variants

A recent study, currently available on bioRxiv* preprint server, shows that a novel protease inhibitor known as nirmatrelvir has potent activity against Omicron variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), but also other variants evaluated in this paper – which supports its potential role in reducing the disease burden from coronavirus disease 2019 (COVID-19).

21 Jan 2022

A validated risk-stratification system to manage COVID-19 outpatients

A group of researchers developed a risk-stratification system from existing scoring methods that are exclusively for outpatients.

20 Jan 2022

Study shows efficacy, safety of oral immunotherapy in one- to three-year-olds with peanut allergy

The majority of young children treated with peanut immunotherapy achieved desensitization after two and a half years of treatment, and one in five remained in remission 26 weeks after treatment ended, according to a randomized controlled trial published in The Lancet.

20 Jan 2022

Research shows a relationship between increased SARS-CoV-2 seroreactivity and antimalarial humoral immunity

Researchers investigate the cross-reactivity of the SARS-CoV-2 with pre-pandemic malaria-exposed sera samples collected from Cambodia.

19 Jan 2022

"Nocebo effect" accounts for 76% of all adverse events in the COVID-19 vaccine trial group

The placebo effect is the well-known phenomenon of a person's physical or mental health improving after taking a treatment with no pharmacological therapeutic benefit – a sugar pill, or a syringe full of saline, for example.

18 Jan 2022

Previous
1
...
51
52
53
54
55
56
57
...
1156
Next

Drug Trial News

Two peanut allergy treatments for children found to be highly effective at inducing remission

Drug used to treat skin and lung cancers slows the progression of ovarian cancer sub-type

Ketamine is rapid, safe, and effective in treating hospitalized suicidal patients

Nanoparticle vaccine effective against eight SARS-CoV-2 variants in non-human primates

Experimental immunotherapy could help treat some people with metastatic breast cancer

Individual dosing of preparatory drug makes stem cell transplants safer for children

Open-label placebo shows promise as therapy for disorders of gut-brain interaction in children

New trial tests the effectiveness of hyperimmune immunoglobulin for hospitalized COVID-19 patients

Study provides a new treatment option for patients with relapsed B-cell lymphoma

Homologous and heterologous COVID-19 booster vaccines found to be safe and immunogenic

More than 5,000 people enrolled in PANORAMIC study for COVID-19 antivirals

Eligible adults urged to take part in world-first COVID-19 study of antivirals

Nirmatrelvir, Molnupiravir, and Remdesivir hold-up against SARS-CoV-2 Omicron variant in vitro

Trastuzumab combined with trimodality treatment for HER2-overexpressing esophageal cancer found to be ineffective

New opportunity to induce remission of peanut allergy in young children through oral immunotherapy

PAXLOVID shown to be highly effective against all SARS-CoV-2 variants

A validated risk-stratification system to manage COVID-19 outpatients

Study shows efficacy, safety of oral immunotherapy in one- to three-year-olds with peanut allergy

Research shows a relationship between increased SARS-CoV-2 seroreactivity and antimalarial humoral immunity

"Nocebo effect" accounts for 76% of all adverse events in the COVID-19 vaccine trial group

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News